source
- FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concernsSummit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
- Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challengesAcquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…